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ABSTRACT
Background
Evidence of reduced cardiovascular morbidity and mortality as well as cost support thiazide
diuretics as the first-line choice for treatment of hypertension. The purpose of this study was to
determine the proportion of senior hypertensives that received thiazide diuretics as first-line
treatment, and to determine if cardiovascular and other potentially relevant comorbidities
predict the choice of first-line therapy.
Methods and Findings
British Columbia PharmaCare data were used to determine the cohort of seniors (residents
aged 65 or older) who received their first reimbursed hypertension drug during the period 1993
to 2000. These individual records were linked to medical and hospital claims data using the
British Columbia Linked Health Database to find the subset that had diagnoses indicating the
presence of hypertension as well as cardiovascular and other relevant comorbidities. Rates of
first-line thiazide prescribing as proportion of all first-line treatment were analysed, accounting
for patient age, sex, overall clinical complexity, and potentially relevant comorbidities. For the
period 1993 to 2000, 82,824 seniors who had diagnoses of hypertension were identified as new
users of hypertension drugs. The overall rate at which thiazides were used as first-line
treatment varied from 38% among senior hypertensives without any potentially relevant
comorbidity to 9% among hypertensives with previous acute myocardial infarction. The rate of
first-line thiazide diuretic prescribing for patients with and without potentially relevant
comorbidities increased over the study period. Women were more likely than men, and older
patients were more likely than younger, to receive first-line thiazide therapy.
Conclusions
Findings indicate that first-line prescribing practices for hypertension are not consistent with
the evidence from randomized control trials measuring morbidity and mortality. The health and
financial cost of not selecting the most effective and least costly therapeutic options are
significant.
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Hypertension signiﬁcantly increases the risk of serious
cardiovascular morbidity and mortality and is the leading
primary diagnosis for patient visits to physicians’ ofﬁces in
Canada [1]. Pharmaceuticals used in the treatment of hyper-
tension constitute the leading therapeutic category of
prescription drugs in Canada, accounting for 20% of total
prescription drug sales in Canada [2]. Decisions concerning
the management of hypertension will therefore have signiﬁ-
cant impact on population health and health care costs. First-
line treatment of hypertension with thiazide diuretics has
been shown to signiﬁcantly reduce serious cardiovascular
morbidity (stroke and myocardial infarction [MI]) and
mortality in randomised controlled trials, with beneﬁts at
least as great as ﬁrst-line treatment with other classes of
antihypertensive drug [3,4,5,6]. Thiazide diuretics are also less
costly than other antihypertensive drugs. Therefore, thiazide
diuretics are the most cost-effective ﬁrst-line therapeutic
option for the majority of patients.
The purpose of this study was to determine whether
prescribing practices are in accordance with this evidence.
Using population-based research datasets at the University of
British Columbia’s Centre for Health Services and Policy
Research, we calculated trends in ﬁrst-line prescribing of
antihypertensive drugs for seniors (residents aged 65 or
older) in the province of British Columbia over the period of
1993 to 2000. We analyse the likelihood of ﬁrst-line thiazide
prescribing as a function of patient age, sex, overall clinical
complexity, and potentially relevant comorbidities.
Methods
Administrative data from public medical, hospital, and
pharmaceutical insurance programs were analyzed to deter-
mine trends in ﬁrst-line hypertension drug use. All residents
of British Columbia are covered under a comprehensive
public health insurance planf o rm e d i c a la n dh o s p i t a l
services. Public insurance for prescription drugs is restricted
to selected populations, but includes universal and compre-
hensive drug coverage for all seniors [7]. Administrative
claims data from British Columbia PharmaCare, the public
drug plan for all seniors, were used to track prescription drug
use for this demographic cohort. Data from the public health
insurance plan for medical and hospital services were used to
identify diagnoses of hypertension and potentially inﬂuential
comorbidities for those seniors who ﬁlled prescriptions for
drugs commonly used in the management of hypertension.
The study cohort included all community-dwelling seniors
who had evidence of ﬁrst-time hypertension drug use and
hypertension diagnosed in administrative databases. The
classes of hypertension drugs were deﬁned by the World
Health Organization Anatomical Therapeutic Chemical
classiﬁcation system, and included angiotensin-converting
enzyme (ACE) inhibitors, angiotensin-II receptor blockers,
beta-blockers, calcium-channel blockers, alpha-antagonists,
thiazide diuretics, nonthiazide diuretics, and other antihy-
pertensives (e.g., reserpine). First-time hypertension drug use
was deﬁned as the receipt of any hypertension drug following
at least one year of eligibility for PharmaCare coverage
during which no prescriptions for any hypertension drugs
were ﬁlled. Eligibility for coverage was measured starting in
January 1992. A patient was considered a ﬁrst-time user only
once; those who stopped drug treatment and then ﬁlled
prescriptions for antihypertensive drugs a year or more later
were only included in the analysis of ﬁrst-line use based on
their initial course of treatment.
The study cohort was limited to the subset of ﬁrst-time
users of antihypertensive drugs who had a diagnosis of
hypertension in administrative data records. This included
patients for whom there was at least one diagnosis of
hypertension (an International Classiﬁcation of Diseases-9
code in the 401.x family) in Medical Services Plan and
Hospital Separations databases spanning two years prior to
the date of ﬁrst-line hypertension treatment and one year
following ﬁrst-line treatment. Each Medical Services Plan
record pertains to a fee-for-service billing and contains one
diagnosis for the physician visit or related service. This is
assumed the primary diagnosis for the visit or service.
Hospital Separations records describe patient stays at the
point of discharge and contain up to 16 diagnoses, all of
which were searched. In order to avoid bias as a result of
under-reporting the diagnosis of hypertension, diagnoses of
hypertension were sought from records spanning two years
prior to and one year following the ﬁrst prescription for
hypertension. Diagnoses occurring after drug use were
included in the study because, for approximately one-third
of users of hypertension drugs, the diagnosis of hypertension
was recorded as the primary diagnosis during follow-up after
the initiation of drug treatment.
Medical and hospital data spanning two years prior to the
date of ﬁrst-time hypertension treatment were searched for
International Classiﬁcation of Diseases-9 diagnostic codes
pertaining to potentially relevant comorbidities. Identiﬁed
using ‘‘Expanded Diagnostic Clusters’’ [8], the diagnoses
sought included acute MI, aneurysm, angina, congestive heart
failure, cardiac arrhythmia, cardiovascular valve disorder,
gout, hyperlipidaemia, ischaemic heart disease, migraine
headache, diabetes mellitus, and chronic renal failure. As
has been done elsewhere [9], these comorbidities were
selected because clinical guidelines, expert opinion, or
marketing information suggested that their presence might
Table 1. List of Potentially Confounding Conditions
Condition Other Hypertension Drugs That
May Be Indicated
Acute MI Beta-blockers or ACE inhibitors
Aneurysm Beta-blockers or calcium channel blocker
(e.g., nimodipine)
Angina Beta-blockers
Ischaemic heart disease Beta-blockers or ACE inhibitors
Congestive heart failure Furosemide, ACE inhibitors, beta-blockers, or
spironolactone
Cardiac arrhythmia Beta-blockers
Cardiovascular valve
disorders
Furosemide, ACE inhibitors, or beta-blockers
Gout (Thiazide diuretics may be contraindicated)
Headaches—Migraine Beta-blockers
Hyperlipidaemia (Antihypertensive drugs that lower lipids have been
suggested such as pindolol, alpha-blockers)
Diabetes mellitus ACE inhibitor
Chronic renal failure Furosemide
DOI: 10.1371/journal.pmed.0020080.t001
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Trends in Thiazide Prescribinginﬂuence the likelihood of a physician prescribing thiazide
therapy; they are not necessarily substantiated by randomized
controlled trial evidence of morbidity or mortality implica-
tions. A list of these diagnoses and their possible effects on
treatment choices is provided in Table 1. Additional
diagnoses, such as mild kidney disease, are also likely to be
relevant, but these are not captured in administrative data.
Patients’ ﬁrst-line therapy was determined by the catego-
ries of drugs that they received on the date they ﬁrst ﬁlled a
hypertension prescription. In addition to patients who
started treatment with the purchase of a thiazide alone or a
combination product that contained thiazides, patients
whose ﬁrst hypertension treatment was a thiazide diuretic
along with another antihypertensive drug were also consid-
ered to be receiving ﬁrst-line thiazide therapy.
Statistical Analysis
The analysis is based on data describing the entire
population of users ﬁtting the protocol deﬁnitions. Summary
statistics describe average cost per day of treatment for each
category of drug and ﬁrst-line treatment choices over time.
Multivariate logistic regression determined the probability
that a patient would receive a thiazide diuretic as a ﬁrst-line
drug treatment. Independent variables for the multivariate
analysis included patient age, sex, and year of ﬁrst prescrip-
tion. As a measure of overall clinical complexity, the
regression included the number of different types of
prescription drug purchased within the year prior to the
patient’s ﬁrst antihypertensive drug purchase. Binary varia-
bles indicating prior diagnosis of comorbidities were in-
cluded as independent variables. The analysis also included a
binary variable that identiﬁed patients who ﬁlled no more
antihypertensive prescriptions during the year following
their ﬁrst antihypertensive drug purchase. Wald chi-square
tests were calculated to determine statistical signiﬁcance.
Results
A total of 82,824 British Columbia residents over age 65
received an antihypertensive drug for their ﬁrst time between
1993 and 2000. Over the period of study, the share of British
Columbia seniors who were ﬁrst-time users of antihyperten-
sive drugs in a given year increased from 1.8% to 2.2%. The
median age of patient at the date of ﬁrst-time hypertension
use was 72; 55% of newly treated seniors were female.
The average cost per days-supply of hypertension treat-
ment received by British Columbia seniors varied by type of
drug prescribed and was affected by policies implemented
over the period of study (Figure 1). Available from 1996
onward, angiotensin-II receptor blockers were the most
expensive treatment options by 2002, costing Can$1.16 per
day of treatment. While the average cost per day of treatment
with calcium-channel blockers had been as high as Can$1.32,
it declined to Can$1.04 following the 1997 implementation of
a reference-based pricing policy [10]. The daily cost of ACE
inhibitors fell from Can$1.00 to Can$0.87 per day, also due to
reference pricing [11]. Owing to increased generic avail-
ability, the cost per day of therapy on beta-blockers fell from
Can$0.59 to Can$0.34 over the period. Over the entire
period, thiazide diuretics were the least expensive treatment
option, costing less than Can$0.01 per day of therapy.
Thiazide diuretics were prescribed as a ﬁrst-line therapy
for less than a third (29%) of newly treated patients. Over
time, the trend in the share of newly treated patients that
received thiazide diuretics as a ﬁrst-line therapy was similar
for those with and without diagnoses indicating potentially
inﬂuential comorbidities. Figure 2 illustrates these time
trends. The shares of patients with and without comorbidity
that received ﬁrst-line thiazide treatment increased from
25% and 16%, respectively, in 1995 to 42% and 23% in 1997.
These shares remained relatively stable thereafter, ending at
42% and 22% in 2000. First-line thiazide diuretic prescribing
as a share of newly treated patients did not exceed 45% at any
point from 1993 to 2000.
Theproportionofnewlytreatedpatientsreceivingthiazides
as ﬁrst-line therapy varied according to the presence of
comorbidity diagnoses (Table 2). Nearly half (39,764) of these
newly treated senior hypertensives had no medical or hospital
records indicating a potentially confounding comorbidity;
38% of these ‘‘uncomplicated’’ patients received thiazides as
ﬁrst-linetreatment.The22%ofnewlytreatedpatientsthathad
multiple comorbidities received thiazides at a rate of approx-
imately 1 in 7 (14%). Those with evidence of previous acute
myocardial infarction received thiazides least frequently (9%).
Figure 1. Average Cost per Day of Therapy Supplied to British Columbia
Seniors by Category of Hypertension Drug
DOI: 10.1371/journal.pmed.0020080.g001
Figure 2. Thiazide Diuretics as Percentage of First-Line Treatments for
Hypertensive Patients with and without Potentially Confounding
Comorbidities
DOI: 10.1371/journal.pmed.0020080.g002
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Trends in Thiazide PrescribingAs shown in Table 3, multivariate logistical regression analysis
indicated that ﬁrst-line treatment was affected by a time trend
(rates of thiazide use increased over the period, p , 0.001),
gender(womenmorelikelytoreceivethiazides,p,0.001),and
age (older patients more likely to receive thiazides, p , 0.001).
The measure of overall clinical complexity (number of differ-
ent drugs used) did not have a signiﬁcant impact. After
adjusting for these factors, all potentially inﬂuential concur-
rent diagnoses other than migraine headache were associated
with a statistically signiﬁcant reduction in the likelihood of
ﬁrst-line thiazide diuretic use. Patients with diagnoses of acute
MI, angina, or chronic renal failure were less than half as likely
to receive thiazide diuretics as those without such diagnoses.
Study Limitations
Despite the advantage that it is population based, this
research study is limited by the use of administrative claims
data. Claims data may result in under-reporting of actual
conditions [12,13]. In an effort to compensate for this, the
deﬁnitions of comorbidities were based on one or more
diagnoses over a two-year period. A further limitation of
claims-based data is that they track only those prescriptions
that are dispensed from pharmacies. This analysis therefore
does not track ﬁrst-line use by way of professional samples
given to patients. Because thiazide diuretics are no longer
patented, none of their manufactures provide professional
samples in British Columbia. Thus, the results may over-
report the true ﬁrst-line use of thiazides.
Discussion
The overall share of British Columbia senior hypertensives
that received thiazide diuretics as ﬁrst-line treatment ranged
from 21% to 34% between 1993 and 2000. Thiazide use was
affected by the presence of diagnoses for certain comorbid-
ities;however, the rates of ﬁrst-line thiazide use were relatively
low (below 45%) for patients both with and without any
evidence of conditions that might inﬂuence treatment choice.
We believe that such rates of ﬁrst-line thiazide use among
newly treated hypertensive seniors are low, given the evidence
for the morbidity and mortality beneﬁt associated with the
ﬁrst-line use of this class of antihypertensive drugs [4,5,6,14]
and the substantial cost differences between products.
Because the cost per day of treatment on alternative
treatments is upwards of 100 times that of thiazide diuretics,
the ﬁnancial consequences of ﬁrst-line treatment decisions
are signiﬁcant, even when limited to the group of ‘‘uncom-
plicated’’ cases. For the subset of patients with no comorbid-
ities, the additional cost to British Columbia PharmaCare in
2000 stemming from decisions to treat newly hypertensive
seniors with nonthiazides was approximately Can$1 million
per year. This additional cost will accumulate for each year
that these incident cases continue to receive treatment. It is
therefore necessary for professional associations and those
who pay for (and beneﬁt from) pharmaceutical beneﬁts to
work together to ensure that prescribing practices more
accurately reﬂect research evidence.
One might conjecture that low rates of ﬁrst-line thiazide
use result from physicians’ concerns regarding the presence
of comorbidity. In our study, approximately half of the newly
treated hypertensive seniors had diagnoses associated with
speciﬁc comorbidities that may inﬂuence prescribers’ beliefs
about the appropriateness of thiazide diuretics. In all
instances except migraine headaches, the presence of a
comorbidity diagnosis predicted a decreased incidence of
ﬁrst-line thiazide use. Some of the associations are rational
and consistent with outcomes evidence. Following acute MI,
for example, beta-blockers and ACE-inhibitors are ﬁrst-line
choices because they have been shown in randomized
controlled trials to reduce morbidity and mortality in
addition to having a blood pressure lowering effect [15,16].
It is encouraging that in accordance with the evidence in this
population, we found that only 9% of patients received
thiazide diuretics as ﬁrst-line therapy. Some of the associa-
tions that we found between comorbidity and ﬁrst-line
antihypertensive choice were not substantiated by evidence
Table 2. Total Newly Treated Patients and Rate of First-Line
Thiazide Use by Comorbidity
Condition Newly Treated
Patients (Number)
Thiazide First-Line
Number Percent
No comorbidities 39,764 14,930 38
Hyperlipidaemia 4,148 1,449 35
Cardiovascular valve disorders 718 238 33
Migraine headaches 511 163 32
Aneurysm 734 227 31
Ischaemic heart disease 2,187 605 28
Gout 670 169 25
Diabetes mellitus 7,951 1,873 24
Congestive heart failure 1,047 241 23
Arrhythmia 2,360 521 22
Angina 3,306 642 19
Chronic renal failure 79 13 16
Multiple comorbidities 19,019 2,611 14
Acute MI 330 29 9
Grand Total 82,824 23,711 29
DOI: 10.1371/journal.pmed.0020080.t002
Table 3. Logistic Regression Results—Odds Ratios
Variable Univariate
Estimates
Multivariate
Estimate
p-Value
Year of first prescription 1.07 1.08 , 0.001
Age at first prescription 1.01 1.01 , 0.001
Sex (1 = female) 1.76 1.59 , 0.001
Only one prescription
(1 = no further fills)
1.32 1.27 , 0.001
Number of different drugs 0.96 0.99 0.097
Cardiovascular valve disorders 0.52 0.92 0.045
Migraine headaches 0.90 0.92 0.212
Aneurysm 0.60 0.83 , 0.001
Hyperlipidaemia 0.75 0.82 , 0.001
Gout 0.55 0.70 , 0.001
Ischaemic heart disease 0.40 0.67 , 0.001
Congestive heart failure 0.40 0.58 , 0.001
Cardiac arrhythmia 0.42 0.56 , 0.001
Diabetes mellitus 0.52 0.54 , 0.001
Angina 0.33 0.47 , 0.001
Chronic renal failure 0.29 0.36 , 0.001
Acute MI 0.13 0.24 , 0.001
DOI: 10.1371/journal.pmed.0020080.t003
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for example, was associated with a statistically signiﬁcant
decrease in thiazide use versus patients without this diagnosis.
This is likely explained based on the reported small increase
in cholesterol associated with thiazides [17], but is not
rational based on the morbidity and mortality evidence from
randomized controlled trials [5,6,17].
Clinical practice guidelines starting in the early 1980s
recognized the beneﬁts of treatment with thiazide diuretics
by recommending them as the ﬁrst-line treatment of choice
for virtually all hypertension patients [18,19,20,21,22,23,24,
25]. Newer guidelines, while acknowledging thiazide diuretics
as a ﬁrst-line choice, increasingly recommended other classes
of antihypertensive drugs as ‘‘alternate’’ ﬁrst-line choices or
recommended other classes for speciﬁc patient populations
[26,27,28]. An example of this is the recommendation against
use of thiazide diuretics for patients with diabetes mellitus. It
was argued that thiazide diuretics might not achieve the same
morbidity and mortality beneﬁts because they increase blood
glucose in some patients. However, this effect of thiazides on
glucose has not diminished the morbidity and mortality
beneﬁt seen in randomized controlled trials: patients with
diabetes achieve similar morbidity and mortality beneﬁt with
thiazides to non-diabetic patients [29]. Similarly, recent
clinical practice guidelines recommend ACE-inhibitors as
the preferred ﬁrst-line therapy for hypertensive patients with
mild kidney disease [28]. Proponents of ACE-inhibitors argue
that hypertensive patients with kidney disease beneﬁt both
from the general antihypertensive effect of ACE-inhibitors
and a speciﬁc ’kidney sparing’ effect associated with this class
of drugs. This theoretical beneﬁt has not been substantiated
in randomized controlled trials [30].
Given that hypertension treatment is one of the fastest
growing drivers of seniors’ drug expenditure in British
Columbia [31], a critical challenge facing clinicians and policy
makers is to use lower-cost therapeutic options whenever they
produce equivalent or superior morbidity and mortality
beneﬁt to patients. This can be a particularly difﬁcult task
when set against a backdrop of marketing claims that draw
associations between marketed products and superior per-
formance for using surrogate markers for sub-populations.
One mechanism for improving the cost-effectiveness of
product selection decision is education. Our study results
show that ﬁrst-line thiazide therapy increased towards the end
of 1995 and through 1996, and then remained at a relatively
stable rate of approximately 30%. The increase in the rate of
ﬁrst-line thiazide prescribing coincided with the publication
of two Therapeutics Letters, produced by the Therapeutics
Initiative at the University of British Columbia, on the topic of
ﬁrst-line hypertension treatment [4,14]. The observed impact
of these letters, which were mailed to all prescribing
physicians in British Columbia in the summer and fall of
1995, has been reported elsewhere [9,32]. Except for this
increase, the rate of ﬁrst-line thiazide therapy did not change
substantially over the study period despite a growing body of
available evidence indicating the morbidity and mortality
beneﬁt of ﬁrst-line thiazide therapy [5,6,33,34]. Policymakers
might consider engaging in regularly reinforced educational
interventions to better inform prescribers regarding the
appropriate cases for selecting lower and higher cost
medicines. Alternatively, or perhaps in conjunction with
educational efforts, innovative forms of incentive pricing or
beneﬁt-sharing may be used to provide both prescribers and
patients the incentive to start with the low cost therapies [35].
Either way, it is incumbent upon the medical profession to
weigh carefully the relative costs and beneﬁts of treatments
for particular patients; for, every additional dollar spent on
drugs without any beneﬁt is a dollar that is unavailable for
other medical or pharmaceutical services.
This analysis predates publication of the largest random-
ized antihypertensive trial designed to answer the question of
which ﬁrst-line antihypertensive is best, the ALLHAT trial
[30]. ALLHAT compared four ﬁrst-line antihypertensive
classes (a thiazide-like diuretic [THZ], an alpha blocker, an
ACE inhibitor, and a calcium channel blocker) in 33,357
patients. The alpha-blocker caused increased cardiovascular
morbidity, and that arm was terminated early [36]. At the end
of the trial, total mortality, coronary heart disease, and end-
stage renal disease were similar for the remaining three arms.
The ﬁrst-line calcium channel blocker caused more heart
failure compared to the THZ and ACE inhibitor. First-line
ACE inhibitor caused more strokes compared to THZ. The
overall conclusion from ALLHAT was that thiazide diuretics
are the preferred ﬁrst-line therapy for hypertension [30].
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Patient Summary
Background High blood pressure (hypertension) is common and
increases the chances of developing heart disease. Different types of
drugs are available for treating blood pressure, and they have been
compared in many different studies. When doctors recommend a
particular drug for a particular patient, they base their decision on the
latest studies, on whether the patient has any other medical problems
that might affect drug choice, and on the price differences between
different drugs. If there are two drugs that have been shown to work
equally well for a particular patient, the doctor should prescribe the
cheaper one.
Why Was This Study Done? The researchers wanted to see whether
doctors follow the latest guidelines when they prescribe drugs for
treating high blood pressure (antihypertensive drugs).
What Did the Researchers Do? They looked at which drugs doctors had
given to people aged over 65 years with high blood pressure in British
Columbia, Canada, from 1993 to 2000. They only looked at prescriptions
for people who had never taken blood-pressure medication before, a
total of 82,824 patients. The drug of choice for most of these patients is a
thiazide. Thiazides belong to a class of drugs called diuretics, sometimes
referred to as water pills. These drugs have been around for a long time
and in most patients they are at least as effective as and much cheaper
than any of the newer drugs.
What Did They Find? The prescription of thiazides in these patients
increased from 22% to 33% during the study period, but it was
consistently lower than it should have been based on the existing
evidence.
What Does This Mean?
Doctors in British Columbia do not prescribe thiazides for seniors with
high blood pressure as much as they should. As a consequence, some
patients don’t get the best treatment and the costs are considerably
higher than they need to be. The reasons are not clear, but the findings
suggest that doctors might not be up-to-date with the latest study
results and guidelines. There have been more studies since 2002 and
more efforts to educate doctors, and it would be interesting to know
whether the current prescription practices better match the latest
results.
More Information Online
The website of the US National Heart, Lung, and Blood Institute (http://
www.nhlbi.nih.gov) has information about antihypertensive drugs and
their characteristics, including facts on a recent big study (called the
ALLHAT study) that compared antihypertensive drugs: http://
www.nhlbi.nih.gov/health/allhat/facts.htmInformation pages from the
Blood Pressure Association, a UK-based charity: http://www.bpassoc.
org.uk/information/information.htmMedline Plus information pages on
blood pressure: http://www.nlm.nih.gov/medlineplus/highbloodpressure.
html
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